Q1 2024 EPS Estimates for Balchem Co. (NASDAQ:BCPC) Lowered by Sidoti Csr

Balchem Co. (NASDAQ:BCPC) – Equities research analysts at Sidoti Csr dropped their Q1 2024 earnings per share (EPS) estimates for shares of Balchem in a research report issued on Wednesday, April 24th. Sidoti Csr analyst K. May now forecasts that the basic materials company will post earnings per share of $0.98 for the quarter, down from their prior estimate of $1.00. The consensus estimate for Balchem’s current full-year earnings is $4.14 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2024 earnings at $1.00 EPS, Q3 2024 earnings at $1.06 EPS, Q4 2024 earnings at $1.06 EPS, FY2024 earnings at $4.10 EPS, Q1 2025 earnings at $1.09 EPS, Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.19 EPS, Q4 2025 earnings at $1.18 EPS and FY2025 earnings at $4.59 EPS.

Separately, StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a research report on Thursday.

Balchem Stock Up 0.5 %

NASDAQ:BCPC opened at $139.26 on Friday. The firm has a market capitalization of $4.49 billion, a price-to-earnings ratio of 41.34, a price-to-earnings-growth ratio of 4.25 and a beta of 0.71. Balchem has a twelve month low of $110.74 and a twelve month high of $159.52. The stock’s 50 day moving average price is $152.25 and its two-hundred day moving average price is $139.84. The company has a quick ratio of 1.38, a current ratio of 2.12 and a debt-to-equity ratio of 0.31.

Balchem (NASDAQ:BCPC) last announced its earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. Balchem had a return on equity of 10.69% and a net margin of 11.77%. The business had revenue of $228.70 million for the quarter, compared to analyst estimates of $234.66 million. During the same quarter last year, the firm earned $0.66 EPS. Balchem’s revenue for the quarter was down 1.6% compared to the same quarter last year.

Insiders Place Their Bets

In other Balchem news, CAO William A. Backus sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the transaction, the chief accounting officer now owns 5,914 shares of the company’s stock, valued at approximately $917,793.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO William A. Backus sold 9,180 shares of Balchem stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the completion of the transaction, the chief accounting officer now directly owns 12,914 shares in the company, valued at approximately $2,019,362.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO William A. Backus sold 7,000 shares of Balchem stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $155.19, for a total value of $1,086,330.00. Following the transaction, the chief accounting officer now owns 5,914 shares of the company’s stock, valued at $917,793.66. The disclosure for this sale can be found here. Insiders have sold 76,630 shares of company stock valued at $11,843,249 in the last 90 days. 1.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in Balchem by 18.0% in the 1st quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock valued at $73,000 after purchasing an additional 72 shares during the period. Cardinal Capital Management boosted its stake in Balchem by 0.4% in the 4th quarter. Cardinal Capital Management now owns 19,539 shares of the basic materials company’s stock valued at $2,922,000 after purchasing an additional 79 shares during the period. Signaturefd LLC boosted its stake in Balchem by 123.0% in the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after purchasing an additional 91 shares during the period. SageView Advisory Group LLC boosted its stake in Balchem by 2.1% in the 3rd quarter. SageView Advisory Group LLC now owns 4,814 shares of the basic materials company’s stock valued at $597,000 after purchasing an additional 98 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in Balchem by 0.7% in the 3rd quarter. Commonwealth Equity Services LLC now owns 14,532 shares of the basic materials company’s stock valued at $1,803,000 after purchasing an additional 104 shares during the period. 87.91% of the stock is currently owned by institutional investors.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.